Stereotaxis, Inc.STXSEarnings & Financial Report
Stereotaxis Inc. is an American publicly traded medical technology company based in St. Louis, Missouri, that makes robotic systems used by physicians to perform minimally-invasive endovascular procedures, including electrophysiology studies and cardiac catheter ablation procedures.
Revenue
$8.8M
Gross Profit
$4.6M
Operating Profit
$-4.0M
Net Profit
$-3.8M
Gross Margin
52.0%
Operating Margin
-45.2%
Net Margin
-43.5%
YoY Growth
95.4%
EPS
$-0.05
Stereotaxis, Inc. Q2 FY2025 Financial Summary
Stereotaxis, Inc. reported revenue of $8.8M (up 95.4% YoY) for Q2 FY2025, with a net profit of $-3.8M (up 34.4% YoY) (-43.5% margin). Cost of goods sold was $4.2M, operating expenses totaled $8.6M.
Key Financial Metrics
| Total Revenue | $8.8M |
|---|---|
| Net Profit | $-3.8M |
| Gross Margin | 52.0% |
| Operating Margin | -45.2% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
Stereotaxis, Inc. Q2 FY2025 revenue of $8.8M breaks down across 2 segments, led by Disposables Service And Accessories at $5.8M (65.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Disposables Service And Accessories | $5.8M | 65.5% |
| Systems | $3.0M | 34.5% |
Stereotaxis, Inc. Revenue by Segment — Quarterly Trend
Stereotaxis, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Disposables Service And Accessories and Systems) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Disposables Service And Accessories | $5.3M | $5.6M | $5.8M | $5.5M |
| Systems | $3.4M | — | $3.0M | $2.0M |
Stereotaxis, Inc. Annual Revenue by Year
Stereotaxis, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $32.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $32.4M |
| 2024 | $26.9M |
| 2023 | $26.8M |
| 2022 | $28.1M |
Stereotaxis, Inc. Quarterly Revenue & Net Profit History
Stereotaxis, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $8.6M | +36.3% | $-5.5M | -64.0% |
| Q3 FY2025 | $7.5M | -18.8% | $-6.5M | -86.6% |
| Q2 FY2025 | $8.8M | +95.4% | $-3.8M | -43.5% |
| Q1 FY2025 | $7.5M | +8.6% | $-5.8M | -77.9% |
| Q4 FY2024 | $6.3M | +38.9% | $-7.5M | -118.5% |
| Q3 FY2024 | $9.2M | +17.9% | $-6.2M | -67.3% |
| Q2 FY2024 | $4.5M | -42.7% | $-5.8M | -129.6% |
| Q1 FY2024 | $6.9M | +5.1% | $-4.5M | -65.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.9M | $4.5M | $9.2M | $6.3M | $7.5M | $8.8M | $7.5M | $8.6M |
| YoY Growth | 5.1% | -42.7% | 17.9% | 38.9% | 8.6% | 95.4% | -18.8% | 36.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $39.5M | $36.0M | $50.9M | $46.7M | $45.7M | $41.2M | $45.6M | $52.3M |
| Liabilities | $19.4M | $19.3M | $34.7M | $35.3M | $37.5M | $34.4M | $34.1M | $33.5M |
| Equity | $14.6M | $11.4M | $10.8M | $6.1M | $2.9M | $1.5M | $6.3M | $13.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.3M | $-3.1M | $-4.3M | $1.3M | $-1.8M | $-3.7M | $-4.2M | $-4.0M |